Conference Call Scheduled for 11:30 AM ET, Thursday, May 1, 2008

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced it would report its financial results for the first quarter of 2008 on Thursday, May 1, 2008 before the open of the financial markets. The announcement will be followed by a conference call scheduled for later that morning, Thursday, May 1, 2008, with the investment community at 11:30 AM ET.

Neoprobe’s President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the company’s results for the first quarter of 2008 during the conference call scheduled for 11:30 AM ET, Thursday, May 1, 2008. The conference call can be accessed as follows:

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000^® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix^® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek^® and RIGScan^® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Neoprobe Corporation
Brent Larson, Vice President / CFO, 614-822-2330
OR
The Trout Group
Tim Ryan, 646-378-2924